FDA advisors quit after approval of Alzheimer's medicine

On Monday, US authorities defied an external panel by approving Biogen's Alzheimer's treatment. Now, several of the participants are stepping down.

Three members of an outside panel that advises the US Food and Drug Administration (FDA) have quit over the past few days.

This is in protest over the decision made by the authority to approve Aduhelm, an Alzheimer's drug developed by Biogen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs